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Summary
Healthy host–microbe mutualism relies on compartmentalization and
proper regulation of systemic and mucosal immune responses. Neverthe-
less, the systemic immune system is frequently exposed to bouts of bac-
teraemia, which can trigger systemic antimicrobial immune reactivity
including CD4+ T cells. Low-level bacteraemia can occur when immune
compartmentalization is compromised, for example in the presence of
innate immune deficiency or following use of non-steroidal anti-inflam-
matory drugs. We generated an Escherichia coli strain expressing a defined
T helper neo-epitope to study systemic antigen-specific antimicrobial
CD4+ T cells and their potential involvement in the pathogenisis of
inflammatory bowel diseases. We found that the dose of bacteria required
for the induction of systemic antimicrobial CD4+ T-cell proliferation was
high and not easily reached under physiological conditions. Importantly,
however, when intestinal barrier function was compromised by induced
damage to the intestinal epithelium, the presence of systemic antimicro-
bial CD4+ T cells specific for a single neo-antigen resulted in dramatically
increased levels of bacterial translocation. This study therefore demon-
strates that systemic antimicrobial CD4+ T-cell reactivity might impact
adversely on the mucosa under conditions of reduced barrier function
and that despite strong mucosal immune regulation, antigen-specific
recognition is still sensitive.
Keywords: antigen specificity; CD4+ T cells; epithelial integrity;
host–microbe mutualism; systemic antimicrobial reactivity.
Introduction
Intestinal colonization with commensal bacteria starts at
birth. The highest bacterial densities, up to 1012 colony-
forming units (CFU)/g, are reached in the large intestine.1
It is well accepted that the intestinal microbiota is benefi-
cial for the host by synthesizing vitamins,2 digesting resis-
tant starch, producing short-chain fatty acids, completing
the bile salt cycle, providing colonization resistance to
pathogens, and promoting maturation of the immune
system.3,4 In return, the host provides the commensal
bacteria with an excellent niche and a constant supply of
nutrients. Functional compartmentalization of the muco-
sal and systemic immune systems, which limits mucosal
responses to the mucosa, is an important component in
the maintenance of host–microbe mutualism.5–8 This
compartmentalization explains why clean laboratory mice
(including specific-pathogen free mice) do not usually
display systemic antibody5 or CD4+ T-cell responses8
directed against the microbiota. However, systemic
responses can occur when immune compartmentalization
is compromised,7 or as a consequence of innate immune
deficiency allowing systemic translocation of intestinal
bacteria.9 Bacteria reaching the blood or the spleen fol-
lowing translocation induce strong adaptive immune
responses.10 Importantly, systemic antimicrobial immune
reactivity against bacterial antigens, such as the outer
membrane porin C (ompC), can be detected even in
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healthy individuals.11 This is probably because, unlike
clean laboratory mice, the human systemic immune sys-
tem is regularly exposed to low levels of gut-derived bac-
teria through episodes of reduced intestinal barrier
function induced by infections,12 mucosal damage due to
dental hygiene,13 non-steroidal anti-inflammatory drugs,14
or dietary fats.15,16 Systemic bacterial translocation has
been demonstrated to induce T helper type 1 cells that
have the capacity to form memory T cells.17
Although systemic bacteria are usually rapidly cleared
by the innate immune system,18–21 the consequences of
induced systemic adaptive antimicrobial (hyper-)reactiv-
ity, in particular antimicrobial CD4+ T-cell reactivity, on
host–microbe mutualism at the mucosa remains unclear.
In humans, systemic antimicrobial hyper-reactivity has
been suggested to be involved in the pathogenesis of
inflammatory bowel disease (IBD).22
To study systemic antimicrobial CD4+ T-cell responses,
we generated an Escherichia coli strain expressing a
defined T helper cell neo-epitope introduced into ompC.
In combination with adoptive transfer of T-cell receptor
transgenic T cells specific for this epitope this allowed us
to study systemic antimicrobial E. coli -specific CD4+ T-
cell responses and their impact on the mucosa. Our
experiments were performed in gnotobiotic mice colo-
nized with an altered Schaedler flora (ASF)23 because
these mice can be colonized with E. coli but do display a
normal immune status.24 Specific pathogen-free mice are
resistant to E. coli colonization and can therefore not be
used for this study.25 We found that although the sys-
temic bacterial load required to trigger systemic antimi-
crobial CD4+ T-cell proliferation was relatively high and
was not reached under steady-state conditions, dextran
sulphate sodium (DSS) -induced damage to the colon
epithelial barrier caused a tremendously increased
bacterial translocation in the presence of systemic antimi-
crobial CD4+ T cells specific for the single added
neo-antigen. Importantly, DSS treatment of gnotobiotic
ASF does not cause overt intestinal inflammation.24 These
data suggest that under situations of disturbed gut integ-
rity, systemic antimicrobial T-cell reactivity, even to a sin-
gle epitope, can have adverse effects on mucosal integrity.
Elucidating the immunological mechanisms involved will
be important to better understand the consequences of
systemic antimicrobial CD4+ T-cell reactivity on host–mi-
crobe mutualism and their role in the pathogenesis and
chronicity of IBD.
Materials and methods
Mice
Germ-free and ASF C57BL/6 and SMARTA mice were
housed at the gnotobiotic Clean Mouse Facility of the
University of Bern. Germ-free mice were bred in flexible
film isolators at the Clean Mouse Facility and absence
of bacterial colonization was verified by plating or liq-
uid cultures of the intestinal contents under aerobic
and anaerobic conditions, as well as performing Gram
and DNA (Sytox green) staining of caecal contents to
detect unculturable bacteria. Specific pathogen-free OT-
II mice on a C57BL/6 background were obtained from
the Zentrale Tierst€alle of the Medical Faculty of the
University of Bern and from the animal facility at the
University of Lausanne. All experiments were performed
in accordance with the Swiss Federal and Cantonal ani-
mal regulations.
Generation of E. coli ompC_gp61 by k red
recombination
The ompC gene of wild-type E. coli MG1655 was first
replaced with a TetRA cassette by k red recombination26
using an amplified TetRA cassette with 40-bp homolo-
gous overhangs in combination with pKD46 (Nature
Technology Corporation, Lincoln, Nebraska, USA) to
target the ompC locus. Clones with successful targeting of
the ompC locus (DompC::TetRA) were screened for using
tetracyline resistance. The ompC_gp61 construct with the
gp61 sequence inserted into loop 7 of ompC was gener-
ated by assembly PCR using a synthetic gp61-coding frag-
ment in combination with PCR amplified 50- and 30-
coding regions of ompC with additional 500-bp homolo-
gous regions to target the ompC locus that had been
replaced with a TetRA cassette. Recombination was again
performed using the targeting construct in combination
with pKD46 (Nature Technology Corporation) and
recombined clones (DompC::ompC_gp61) were identified
by positive selection for loss of TetRA using fusaric
acid.27 Fifty clones were isolated and sequenced to check
for mutations.
Escherichia coli strains, cultures and quantification
Wild-type E. coli MG1655 was used as the parental strain
to generate the ompC-deficient E. coli ΔompC (DompC::
TetRA) and E. coli ompC_gp61 (DompC::ompC_gp61).
Escherichia coli deficient in both ompC and ompF (E. coli
ΔompCΔompF) was a generous gift from Prof. Robin
Ghosh.28 To grow E. coli, a single colony was inoculated
in fresh Luria–Bertani (LB) medium and grown for 16 hr
at 37° with shaking at 160 rpm. Bacteria were collected
by centrifugation (4000 g for 10 min at 4°) and the bac-
terial pellet was washed with sterile PBS. Pellets were re-
suspended in sterile PBS and the volume was adjusted to
obtain the desired amount of CFU in 500 ll for gavage
or intravenous injection. To assess the bacterial load in
the blood, blood was collected in heparin tubes and 50 ll
of blood was plated on LB medium. To measure the bac-
terial load in faecal pellets, spleen, liver, or mesenteric
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lymph nodes (MLN), the samples were weighed and put
into 1 ml PBS containing 01% Tergitol (Sigma, St Louis,
Missouri, USA). The samples were disaggregated in a
Tissuelyser at 30 Hz for 3 min. Then, 50 ll of the tissue
suspension was plated on LB medium. Escherichia coli
and Lactobacillus were distinguished based on colony
morphology and CFU were counted and normalized to
the weight of the organs.
In vitro high osmolarity survival test
104 CFU of the different E. coli strains were incubated at
room temperature in either 1 ml of 015 M or 15 M
NaCl. Fifty microlitres of the bacterial suspension was
sampled before and 1–3 hr after incubation and plated.
Cell isolation from the colon lamina propria
Colons were flushed with Dulbecco’s Phopsphate-Buffered
Saline (DPBS) without CaCl2 and MgCl2 (Invitrogen,
Carlsbad, California, USA) and opened longitudinally. The
colon was then cut into 3–5 mm pieces and washed four
or five times in 20 ml DPBS containing 05 mM EDTA
and 10 mM HEPES (Invitrogen) at 37° with shaking at
220 rpm to remove the epithelial cell layer. The solution
was then transferred into Iscove’s modified Dulbecco’s
medium (IMDM; Invitrogen) containing 05 mg/ml colla-
genase Type VIII (Sigma) and 50 U DNase I to be digested
for 40 min at 37° with shaking at 220 rpm. Undigested
colon pieces were disaggregated using an 18G needle (BD
Biosciences, San Jose, California, USA) and cell suspension
was washed with IMDM at 800 g for 10 min. The cell pel-
let was resuspended in 10 ml IMDM and poured onto a
30%/100% Percoll gradient (GE Healthcare, Little Chal-
font, United Kingdom). Following centrifugation at 680 g
for 30 min with the acceleration and brake turned off, cells
lying at the 30%–100% interphase were collected and used
for FACS staining.
Magnetic cell sorting
Spleens and MLN were digested with 1 U/ml liberase for
30 min at 37° and disintegrated to obtain single cell sus-
pensions. Following centrifugation at 450 g for 5 min, the
cell pellet was re-suspended in 1 ml of 088% NH4Cl for
3 min to lyse the red blood cells. Cells were washed in
IMDM (Invitrogen) and re-suspended in 300 ll of MACS
buffer (2% fetal calf serum and 2 mM EDTA in PBS). For
CD4+ T-cell enrichment 40 ll of CD4 microbeads (Mil-
tenyi Biotec, Bergisch Gladbach, Germany) was added to
the cell suspension and incubated for 30 min at 4°. For
CD11c+ dendritic cell enrichment, 40 ll of CD11c
microbeads (Miltenyi Biotec) was used. After washing in
MACS buffer, the cell suspension was filtered through a
MACS pre-separation filter (Miltenyi Biotec) and then
added to an MS column (Miltenyi Biotec) on an Octo-
MACS Separator (Miltenyi Biotec). Positively labelled
cells were sorted according to the manufacturer’s instruc-
tions and purity was assessed by flow cytometry.
CFSE and CellTrace violet labelling
The MACS-enriched CD4+ T cells were re-suspended in
PBS at 1 9 107 cells/ml. Cells were labelled with 5 lM
carboxyfluorescein succinimidyl ester (CFSE; Invitrogen)
or with 5 lM CellTrace violet (Invitrogen) and incubated
at 37° for 10 min, followed by the addition of 2% fetal
calf serum. After centrifugation for 5 min at 450 g, the
supernatant was discarded and the cells were washed in
PBS. The cell pellet was re-suspended in PBS at
6 9 107 cells/ml and 500 ll of CFSE-labelled CD4+ T
cells were injected into the tail vein.
Preparation of crude outer membrane protein fractions
An overnight culture of the E. coli strain of interest was
diluted 100-fold in 500 ml fresh LB medium. The bacteria
were grown to an optical density 05 (measured at
600 nm) and were harvested by centrifugation at 3500 g
for 10 min. The bacteria pellet was resuspended in 5 ml
of 20 mM sodium phosphate buffer (pH 7.1) and the
bacteria were lysed by sonication (six cycles, one cycle:
30 seconds sonication and 30 seconds cooling on ice).
The lysed bacteria were then incubated at room tempera-
ture for 35 min in 05% sodium N-lauryl sarcosinate
(Sigma). Following centrifugation at 3000 g for 1 min,
the supernatant was collected. Outer membrane protein
fraction was enriched in ompC by ultracentrifugation at
393 000 g for 14 min. The pellet containing ompC-
enriched outer membrane protein was resuspended in
20 mM PBS containing 1% sodium dodecyl sulphate.
In vitro proliferation assay
CD4+ T cells and dendritic cells were isolated from the
spleen and lymph nodes by MACS enrichment. Then,
2 9 105 CFSE-labelled CD4+ T cells and 5 9 104 DC
were added to individual wells of round-bottom plates
(Sarstedt, Newton, North Carolina, USA) and incubated
with 1 lg/ml of aCD3, 2 ng of gp61 peptide, or 1–
100 lg/ml of outer membrane proteins that are enriched
in ompC. CD4+ T-cell proliferation was assessed after
5 days of culture using CFSE dilution as a marker of pro-
liferation.
Flow cytometry
Cells were washed twice with PBS and then stained with
an eFluor506 fixable viability dye (eBioscience, San Diego,
California, USA) in PBS for 30 min at 4°. Cells were then
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washed with FACS buffer containing 2% fetal calf serum
(Invitrogen), 25 mM EDTA (MP Biomedicals, Santa Ana,
California, USA) and 01% NaN3 (Sigma) in PBS. For cell
surface marker staining, the cell pellet was re-suspended
in 100 ll of antibodies diluted in FACS buffer and
stained for 15 min at 4°. The following monoclonal anti-
bodies were used: CD4-PacificBlue clone RM4-5 (Biole-
gend, San Diego, California, USA), CD90.2-AlexaFluor700
clone 30-H12 (Biolegend), Va2-Biotin clone B20.1 (BD
Biosciences) in combination with Streptavidin-allophyco-
cyanin (APC) (BD Biosciences), CD3-AlexaFluor700 clone
17A2 (Biolegend), CD25-Peridinin chlorophyll protein-
Cy5.5 clone PC-61 (Biolegend), CD44-APC-Cy7 clone
Im7, CD27-APC clone LG.3A10 (Biolegend), Foxp3-Alex-
aFluor700 clone FJK-16s (eBioscience), CD19-Alexa-
Fluor700 clone 6D5 (Biolegend), CD11b-APC clone MI/
70, CD11c-PE clone HL3 (BD Biosciences) and IA/IE-
AlexaFluor700 clone M5/114.15.2 (Biolegend). For intra-
cellular cytokine staining, cells were first stimulated with
50 ng/ml PMA (Sigma) and 750 ng/ml ionomycin (Invit-
rogen) in the presence of 10 lg/ml Brefeldin-A (Sigma)
for 4 hr at 37°. Cells were then washed twice with PBS
and the staining with viability dye and cell surface mark-
ers was performed as described above. After surface stain-
ing, cells were fixed and permeabilized in BD cytofix/
cytoperm (BD Biosciences) for 10 min at room tempera-
ture in the dark. Following washing with BD wash buffer,
cells were stained with following monoclonal antibodies
in BD wash buffer overnight: interferon-c-FITC clone
XMG1.2 (BD Biosciences) and interleukin-17 (IL-17) -
phycoerythrin clone TC11-18H10 (BD Biosciences).
Acquisition was performed on a FACS LSR II SORP (BD
Biosciences) and data analysis was performed using
FLOWJO software (Tree Star, Ashland, Oregon, USA) and
PRISM (GraphPad, La Jolla, San Diego, California, USA).
The proliferation index from CFSE dilution profiles was
calculated using FLOWJO software (TreeStar).
DSS treatment
For DSS (MP Biomedicals) treatment, DSS powder was
dissolved in sterile water (Baxter) and sterile filtered. For
DSS experiments with SMARTA T-cell transfer, ASF mice
were treated with 2% DSS in the drinking water for
9 days. Two days after the start of the DSS treatment,
ASF C57BL/6 mice received 3 9 107 CFSE-labelled
SMARTA T cells followed by gavage or intravenous injec-
tion with E. coli the following day.
Albumin ELISA
Albumin levels in caecal contents were measured using
the Mouse albumin ELISA kit (Bethyl Laboratories,
Montgomery, Texas, USA). Nunc-Immuno Plates C96
MaxiSorp (Milian, Gahanna, Ohio, USA) were coated
with 50 ll of unlabelled goat anti-mouse albumin anti-
body (1 : 200 in 01 M bicarbonate buffer) overnight at
4°. After washing with 005% Tween (Sigma) in PBS and
blocking in 1% BSA in PBS, standards (1 mg/ml) and
samples (resuspended in PBS) were added to the plate
and serial dilutions (1 : 3) were performed. After incuba-
tion for 2 hr at room temperature, plates were washed
followed by the addition of 50 ll of horseradish peroxi-
dase-conjugated goat anti-mouse albumin antibody (1 in
33 000 in 1% BSA/PBS) for 1 hr at 37°. After washing,
the plates were developed using 100 ll of TMB substrate
(Biolegend) and stopped using 1M sulphuric acid. The
plates were read at 450 nm and analysis was performed
with GRAPHPAD PRISM (Graphpad).
Cytokine multiplex assay
The cytokines IL-18, IL-6, CXCL1, IP-10/CXCL10, MCP-
2/CCL2, MCP-3/CCL7, MIP-1a/CCL3, and RANTES/
CCL5 in serum were measured using the ProcartaPlex
Mouse Cytokine & Chemokine Panel 1 assay (eBio-
science) according to the manufacturer’s instructions.
Statistics
The unpaired t-test was used to assess statistical signifi-
cance between two groups unless stated otherwise. For
non-normally distributed data sets, the non-parametric
two-tailed Mann–Whitney test was used. P-values below
005 were considered significant. GRAPHPAD PRISM software
(GraphPad) was used to perform the statistical tests.
Results
Generation of a recombinant E. coli MG1655 strain
expressing the gp61 T helper cell neo-epitope
To study antigen-specific antimicrobial CD4+ T-cell
responses we generated a recombinant E. coli MG1655
strain expressing the lymphocytic choriomeningitis virus-
derived I-Ab-restricted T helper cell epitope gp61. This
peptide is recognized by T-cell receptor transgenic
SMARTA T cells.29 This epitope was chosen because of
the available experimental tools and although it is origi-
nally virus-derived, it has now been introduced into a
purely bacterial background. The sequence encoding the
gp61 epitope was codon optimized for E. coli and
inserted into loop 7 of the outer membrane porin C
(ompC) of E. coli MG1655 (Fig. 1a). The chromosomal
wild-type ompC gene was replaced with the modified
ompC_gp61 by k red recombination (see Materials and
methods section).26 This approach was chosen (i) to
ensure stable chromosomal integration, rather than plas-
mid-based expression with the risk of plasmid loss
in vivo, and (ii) because the integration site in loop 7 of
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ompC has previously been shown to be immunogenic
and suited for antigen display.30 Multiple E. coli clones
that had successfully recombined were isolated and
sequenced to check for unwanted mutations introduced
during the process. One clone displayed a completely
mutation-free amino acid sequence for the mature ompC
and a single mutation (V9N) within the hydrophilic H-
region of the signal peptide, which is cleaved off (see
Supplementary material, Fig. S1). The cleavage site in the
C-region of the signal peptide remained intact. This
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Figure 1. In vitro characterization of Escherichia coli ompC_gp61. (a) Mutation-free amino acid sequence of ompC after insertion of the gp61
epitope into loop 7. (b) In vitro growth curve in Luria–Bertani (LB) medium. Fifty millilitres of LB medium was inoculated with one colony of
either wild-type E. coli or E. coli ompC_gp61. (c) 104 CFU of the indicated E. coli strains were treated with 015 M or 15M NaCl at room temper-
ature. (d) Germ-free C57BL/6 mice (five mice per group) were gavaged with 103 CFU of the indicated E. coli strains and colonization levels in
faecal pellets were followed. Data shown are representative of two or three independent experiments. Error bars represent mean  SD.
***P < 00005.
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E. coli strain (DompC::ompC_gp61) is referred to as E. coli
ompC_gp61.
We deliberately generated our own novel antigen-speci-
fic antimicrobial T-cell model to be able to perform very
precise and well-controlled gnotobiotic experiments.
Using this model we can generate basically identical
microbiotas that only differ in one single defined epitope
coming from one single species (E. coli). The T-cell
receptor transgenic CBir1 model, which is specific for a
flagellin-derived epitope,31 has two important caveats in
this respect. First, flagellin is expressed by a variety of
different species, and second, this makes it impossible,
even using gnotobiotic technology, to generate a corre-
sponding control microbiota that lacks the flagellin epi-
tope.
We first compared the fitness of the wild-type E. coli
and the modified E. coli ompC_gp61. Both strains
showed identical in vitro growth in standard LB broth
(Fig. 1b). We next tested the survival of wild-type E. coli,
E. coli ompC_gp61, E. coli DompC and E. coli DompC-
DompF in high osmolarity conditions (Fig. 1c) as ompC
is known to be up-regulated during high osmolarity con-
ditions.32 Escherichia coli DompC and E. coli DompC-
DompF were both included as controls because ompF is
known to be able to compensate for ompC function.33,34
Modification of ompC in E. coli ompC_gp61 did not
affect its ability to survive under increased osmotic stress
in vitro (Fig. 1c). Although deficiency of ompC alone had
no effect in this in vitro assay, E. coli deficient in both
ompC and ompF had reduced survival under high osmo-
larity conditions (Fig. 1c). We next tested the coloniza-
tion capacity of these strains in vivo. Escherichia coli
ompC_gp61 colonized germ-free C57BL/6 mice to the
same levels as wild-type E. coli (Fig. 1d). As a control in
this in vivo assay, we found that only E. coli DompC-
DompF displayed reduced colonization capacity. This
demonstrated that the modified E. coli ompC_gp61 strain
had comparable fitness to the parent strain under in vitro
and in vivo conditions.
Immunogenicity of E. coli ompC_gp61
We next tested whether the gp61 epitope within E. coli
ompC_gp61 was expressed and could be processed and
presented to CD4+ T cells by dendritic cells in vitro. Sple-
nic C57BL/6 dendritic cells were incubated overnight with
a fraction of enriched outer membrane proteins. Func-
tional presentation was assessed by adding CFSE-labelled
gp61-specific SMARTA T cells to the cultures the next
day. In vitro proliferation by CFSE dilution was measured
5 days later (Fig. 2a). Only outer membrane proteins
from E. coli ompC_gp61 but not from wild-type E. coli
or E. coli DompC resulted in the proliferation of gp61-
specific SMARTA T cells (Fig. 2a), demonstrating the
antigen specificity of the model. This also confirmed that
the mutation in the signal peptide (see Supplementary
material, Fig. S1) did not affect trafficking of ompC_gp61
to the outer membrane. Importantly, none of the protein
fractions induced proliferation of polyclonal C57BL/6 T
cells, further demonstrating an antigen-specific effect. As
controls, antigen-specific stimulation with gp61 peptide
alone induced proliferation of SMARTA T cells only
while polyclonal stimulation with aCD3 induced prolifer-
ation of both SMARTA and C57BL/6 T cells (Fig. 2a).
To test immunogenicity and antigen-specificity of the
E. coli ompC_gp61/SMARTA system in vivo, 3 9 107
CFSE-labelled SMARTA T cells were transferred into
wild-type C57BL/6 mice. One day later, mice were immu-
nized intravenously with either 108 CFU E. coli
ompC_gp61 or wild-type E. coli. As a positive control,
mice were injected with gp61 peptide in combination
with the Toll-like receptor 9 ligand CpG. SMARTA T-cell
proliferation in spleen and MLN was assessed by measur-
ing CFSE dilution (Fig. 2b) and the proliferative index
was calculated (Fig. 2c) 2 and 5 days later. As expected,
wild-type E. coli did not induce proliferation of CFSE-
labelled SMARTA T cells. In contrast, intravenous E. coli
ompC_gp61 specifically induced proliferation of
SMARTA T cells. Interestingly, proliferation was restricted
to the spleen and not observed in MLN. In contrast, con-
trol injections of gp61 peptide and CpG resulted in the
proliferation of SMARTA T cells in both the spleen and
MLN. Neither E. coli ompC_gp61 nor wild-type E. coli
induced proliferation of transferred CFSE-labelled ovalbu-
min-specific OT-II cells, further demonstrating the anti-
gen specificity of the model (see Supplementary material,
Fig. S2).
Threshold for systemic antimicrobial CD4+ T-cell
responses
Since systemic reactivity against ompC can be measured
in healthy humans,11 we next determined the load of sys-
temic bacteria that is required to trigger antigen-specific
antimicrobial CD4+ T cells in our model. We transferred
3 9 107 CFSE-labelled CD4+ SMARTA T cells into wild-
type C57BL/6 mice and 1 day later a range of 103–
108 CFU of E. coli ompC_gp61 were given intravenously.
As a negative control, a high dose of 108 CFU wild-type
E. coli was administered. Proliferation of antigen-specific
CD4+ T cells was assessed 6 days later by CFSE dilution
(Fig. 3a,b) and calculation of the proliferative index
(Fig. 3c). We found that a relatively high dose of 105–
106 CFU E. coli ompC_gp61 was required for induction
of an efficient proliferative E. coli (gp61)-specific T-cell
response, which we defined as greater than three cell divi-
sions (Fig. 3a). This threshold level is likely to be under-
estimated because of the high number of transferred
SMARTA T cells and the possibility of bacterial in vivo
proliferation.
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Figure 2. In vivo immunogenicity of live Escherichia coli ompC_gp61. (a) 5 9 104 splenic C57BL/6 dendritic cells (DC) were incubated overnight
either with 5 lg/ml outer membrane protein fractions from the indicated E. coli strains, 2 ng/ml gp61 peptide, or 1 lg/ml aCD3. The next day
2 9 105 CFSE-labelled SMARTA or C57BL/6 CD4+ T cells were added and proliferation was measured 5 days later by flow cytometry. (b)
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type E. coli, 108 CFU E. coli ompC_gp61, or 5 nmol CpG + 50 lg gp61 peptide were injected intravenously. SMARTA T-cell proliferation was
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spleen at day 5. Data shown are representative of two or three independent experiments. ***P < 00005.
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Impact of colonization status on threshold dose
It is known that the colonization status of the host can
impact on systemic immunity.35–37 In particular, germ-
free mice that have an immature and underdeveloped
immune system or mice treated with antibiotics have
impaired innate and adaptive immune responses in mod-
els of viral and bacterial infections.35–37 We therefore
tested whether the colonization status of the recipient
mouse could have an impact on the observed bacterial
threshold for the induction of systemic CD4+ T-cell prolif-
eration. CFSE-labelled CD4+ SMARTA T cells (3 9 107)
were adoptively transferred into germ-free mice or gnoto-
biotic mice colonized with the ASF, a minimal flora con-
sisting of eight bacterial species,23 that has previously been
demonstrated to normalize the intestinal immune system
by inducing regulatory T cells.24 One day after SMARTA
T-cell transfer, the mice were systemically challenged with
106 or 108 CFU of E. coli ompC_gp61. Six days later,
E. coli-specific T-cell proliferation was measured by CFSE
dilution (Fig. 4a,b) and the proliferative index was calcu-
lated (Fig. 4c). Induction and magnitude of antigen-speci-
fic T-cell proliferation in the spleen was independent from
the colonization status of the recipient (Fig. 4a). This was
also reflected in the proportion of CFSElo cells (Fig. 4b)
and the proliferative index (Fig. 4c).
Levels and kinetics of bacteraemia in the blood
following intravenous E. coli application
We next examined the levels and kinetics of bacteraemia
induced following intravenous injection of E. coli
ompC_gp61 to better understand the rather high thresh-
old level of 105–106 CFU and to ask what levels of bacter-
aemia the systemic immune system is exposed to over
time. We determined the kinetics of bacterial clearance in
the blood following intravenous injection of 104, 106 or
108 CFU E. coli ompC_gp61 (Fig. 5a). Although 104 CFU
are cleared from the peripheral blood to below detectable
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Figure 3. Threshold for induction of systemic antimicrobial CD4+ T-cell responses. (a) 3 9 107 CFSE-labelled SMARTA T cells were adoptively
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levels in <1 hr, the threshold dose of 106 CFU caused a
bacteraemia for 4–6 hr, and 108 CFU persisted for more
than 12 hr (Fig. 5a). Most of these bacteria are probably
cleared very quickly by the innate immune system, but
some bacteria are trapped in the spleen and the liver and
therefore were detectable in these organs up to 8 hr post-
challenge, even following a low dose of 104 CFU
(Fig. 5b). Therefore, despite rapid clearance from the
blood, bacteria can persist for longer time periods in the
spleen or liver. Importantly, persistence of bacteria, par-
ticularly in the spleen, has the potential to induce strong
adaptive responses.10
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Consequences of systemic antimicrobial CD4+ T-cell
reactivity following intestinal barrier disruption by
DSS
We next investigated whether the threshold for systemic
antimicrobial CD4+ T-cell responses is altered following
disruption of intestinal barrier function and epithelial
permeability. To induce damage to the colon epithelium
we treated wild-type gnotobiotic ASF-colonized C57BL/6
mice with 2% DSS in the drinking water. Importantly,
gnotobiotic ASF C57BL/6 mice are not E. coli coloniza-
tion resistant (Fig. 6a) and gnotobiotic ASF mice do not
display lethality following DSS treatment, as observed for
germ-free mice.38 Furthermore, we have previously shown
that DSS treatment of gnotobiotic ASF mice does not
result in overt intestinal inflammation as observed in
specific pathogen-free mice.24 Therefore, DSS treatment
of ASF mice predominantly affects barrier function and
does not induce overt inflammation. This made it an
ideal model to study subclinical bacterial translocation.
CFSE-labelled SMARTA T cells were adoptively trans-
ferred into C57BL/6 recipients 2 days after initiation of
DSS treatment and 1 day later mice were orally gavaged
with 1010 CFU of E. coli ompC_gp61 or wild-type E. coli.
Bacterial translocation was measured in MLN, liver and
spleen 6 days later (Fig. 6b,c).
Both wild-type E. coli and E. coli ompC_gp61 colonized
ASF C57BL/6 mice to comparable levels in the presence
or absence of DSS (Fig. 6a). Escherichia coli ompC_gp61
reached slightly lower colonization levels compared with
wild-type E. coli (not statistically significant) in gnotobi-
otic ASF mice in the absence of DSS. The in vivo colo-
nization fitness of wild-type E. coli and E. coli
ompC_gp61 in germ-free mice was identical (Fig. 1d),
but this might indicate that E. coli ompC_gp61 has a
slightly reduced colonization fitness compared with wild-
type E. coli in ASF mice where it has to compete against
other bacteria. Nevertheless, in the presence of DSS treat-
ment the colonization levels for wild-type E. coli and
E. coli ompC_gp61 were identical again. In the absence of
DSS treatment very limited translocation of E. coli (wild-
type and ompC_gp61) to MLN (Fig. 6b), liver and spleen
(Fig. 6c) was observed in the presence of transferred
gp61-specific SMARTA T cells.
Treatment with DSS only marginally increased the level
of translocation of wild-type E. coli and endogenous Lac-
tobacillus. Translocation of other ASF species, such as
Bacteroides, was not tested because translocation of these
non-gp61-expressing ASF species is probably a bystander
effect. The Lactobacillus ASF species is the only ASF spe-
cies able to grow aerobically on LB plates, which is why it
is reported here.
However, in the combined presence of gp61-specific
CD4+ T cells and E. coli ompC_gp61 colonization, DSS
treatment resulted in a dramatic increase of translocation
of E. coli (and Lactobacillus) to MLN, liver and spleen
(Fig. 6b,c). This effect was absolutely dependent on the
presence of the gp61-specific SMARTA T cells because
DSS treatment of ASF mice colonized with either wild-
type E. coli or E. coli ompC_gp61 in the absence of trans-
ferred SMARTA T cells (only endogenous C57BL/6 T cells
present) did not induce bacterial translocation to liver or
spleen (Fig. 6c). It is therefore not an intrinsic effect of
the modified E. coli ompC_gp61 strain. These data indi-
cated that during DSS-induced epithelial damage, the
transferred systemic E. coli-specific CD4+ SMARTA T
cells recognized the cognate gp61 epitope derived from
E. coli ompC_gp61, resulting in increased bacterial
translocation.
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We also measured intestinal permeability by assessing
albumin concentrations in the caecal content. Whereas
increased permeability was clearly increased in DSS-treated
groups compared with non-DSS-treated, no significant dif-
ferences between the wild-type E. coli and E. coli
ompC_gp61 groups were observed (see Supplementary
material, Fig. S3). This suggests that increased bacterial
numbers in liver and spleen might reflect increased bacterial
proliferation, or that quantifying albumin in caecal content
does not reflect the same mechanism of permeability that
leads to the increased numbers of bacteria observed.
We next measured whether the transferred CFSE-
labelled CD4+ SMARTA T cells efficiently homed to the
colon and whether they proliferated under these different
conditions. Although the transferred SMARTA T cells
were readily detectable in the spleen and MLN, we could
not detect any signs of proliferation (Fig. 7a) or
activation as measured by surface activation markers (see
Supplementary material, Fig. S4). This is probably
because the levels of translocated E. coli ompC_gp61 in
the presence of DSS (Fig. 6c) did not reach the threshold
required to induce proliferation. Only a very small popu-
lation of E. coli (gp61) -specific SMARTA T cells could
be detected in the colon lamina propria in all experimen-
tal groups (Fig. 7a). In addition, we could not detect any
differences in the production of interferon-c or IL-17 by
the transferred CFSE+ SMARTA T cells or the endoge-
nous CFSE T-cell population between the different
groups (Fig. 7b). This, surprisingly rather non-responsive
T-cell phenotype was not caused by conversion of the
transferred SMARTA T cells to a Foxp3+ regulatory phe-
notype in the colon, MLN or spleen (see Supplementary
material, Fig. S5). Furthermore, the difference in bacterial
translocation following DSS treatment in the presence of
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E. coli ompC_gp61 or wild-type E. coli was not caused by
differential activation of the intestinal innate immune sys-
tem or by changes in the inflammatory status between
the groups, as determined by measuring cytokine levels in
the serum (see Supplementary material, Fig. S6).
Although there was a trend towards increased levels of
IL-6 in the DSS-treated groups colonized with E. coli
ompC_gp61, this did not reach statistical significance (see
Supplementary material, Fig. S6).
The lack of efficient homing of the transferred
SMARTA T cells to the colon lamina propria (Fig. 7a)
could be due to the intestinal niche being completely
occupied by the endogenous C57BL/6 T-cell population.
We therefore repeated the same experimental set up in T-
cell (and B-cell) -deficient ASF RAG-1/ recipients with
no endogenous T-cell compartment. Although we
observed a higher proportion of a4b7
+ SMARTA T cells
in the spleen of DSS treated RAG-1/ mice colonized
with E. coli ompC_gp61 compared with wild-type E. coli
(Fig. 7c,d), we again did not observe efficient homing of
Va2+ T cells to the colon lamina propria even in the
absence of endogenous T cells (see Supplementary mate-
rial, Fig. S5). This indicated that DSS treatment of gnoto-
biotic ASF mice does not result in sufficient intestinal
inflammatory signals to efficiently attract antigen-specific
T cells.
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We therefore conclude that the presence of systemic
E. coli (gp61)-specific antimicrobial SMARTA T cells has
a detrimental impact on mucosal integrity under certain
conditions. It remains unclear how exactly the SMARTA
T cells exert this effect at the mucosa. It is therefore
important to further dissect the detrimental versus benefi-
cial consequences of systemic antimicrobial T-cell reactiv-
ity for mucosal homeostasis.
Discussion
Immune compartmentalization of the mucosal and sys-
temic immune system is critical for the maintenance of
host–microbe mutualism5,7,8 and its breakdown can result
in systemic antimicrobial immune reactivity.5,7 Innate
immune function is crucial to control microbes that
translocate into the mucosal tissues and hence innate
immune deficiency results in the induction of systemic
antimicrobial antibodies to control systemic bacteraemia.9
In addition, mutations in innate immunity genes are
often associated with autoinflammatory diseases including
IBD.39–41 The role of systemic antimicrobial CD4+ T-cell
reactivity in host–microbe mutualism, however, remains
less clear.
Antimicrobial T-cell responses have previously been
characterized for example using T-cell receptor trans-
genic CBir1 mice.31 This model allows the measurement
of immune responses against flagellated bacteria
expressing the flagellin antigen CBir1. As flagellin is
expressed by a wide range of bacterial species, the
CBir1 model does not allow a precise study of antigen-
specific antimicrobial reactivity against a single bacterial
species (or even a single species-specific epitope). Fur-
thermore, even using gnotobiotic technology, it is
impossible to generate identical microbiotas where the
only difference is the lack or presence of the flagellin
epitope for experimental purposes. Therefore, to mea-
sure antigen-specific antimicrobial CD4+ T-cell
responses in precisely defined experimental settings, we
deliberately generated a novel model to study species-
specific antimicrobial T-cell responses. We generated a
genetically modified E. coli ompC_gp61 strain that
expresses the lymphocytic choriomeningitis virus-derived
T helper cell epitope gp61, allowing the measurement
of specific antimicrobial T-cell responses against a
defined antigen. The gp61 epitope was inserted into
loop 7 of ompC because systemic immune reactivity
against ompC has previously been observed in IBD
patients,42 making this a clinically relevant antigen in
the context of IBD. The inserted gp61 is therefore a
true bacterial neo-antigen and it is irrelevant that it
was originally identified in a virus.
Using this new model, we found that the threshold for
induction of proliferation of systemic antimicrobial T-cell
proliferation was very high. The threshold for
proliferation was so high that it could not even be
reached following DSS treatment to induce damage to the
colon epithelium. This high threshold for proliferation is
probably due to rapid clearance of systemic bacteria by
the innate immune system. In addition, high enough
numbers of live bacteria need to be trapped in the spleen,
for example in marginal zone macrophages,18 for long
enough to induce an adaptive antimicrobial T-cell
response. This is in line with the notion that the systemic
immune system is not tolerant to the presence of gut-
derived bacteria6 and has evolved to respond to only the
persistent presence of a high dose of bacteria.
Although bacterial translocation induced by DSS treat-
ment did not induce antimicrobial T-cell proliferation,
the presence of antimicrobial CD4+ T helper cells during
DSS treatment had a detrimental effect on bacterial
translocation by dramatically increasing the number of
bacteria that translocated to the spleen or liver. This effect
was strictly dependent on the presence of the transferred
SMARTA T cells. This is therefore a clear indication that
systemic antimicrobial T-cell (hyper-)reactivity can have
detrimental consequences for host–microbe mutualism.
Interestingly, this is in contrast to systemic antimicrobial
antibody responses that have been shown to be beneficial
in the face of systemic bacteraemia due to innate immune
deficiency.9 This suggests that systemic antimicrobial anti-
body and T-cell responses might be regulated differently
and that different immune mechanisms are in place to
ensure host–microbe mutualism.
The exact mechanism by which the presence of
microbe-specific CD4+ T cells mediated increased
bacterial translocation remains unclear as we could,
surprisingly, detect very few interferon-c-, IL-17- or
IL-10-producing SMARTA T cells in the colonic lamina
propria. Although it is known that regulatory T-cell con-
version to an oral antigen occurs in the MLN at around
day 5 followed by migration to the colon and subsequent
regulatory T-cell proliferation in the colon,43 we could
not detect any regulatory T-cell conversion in colon or
MLN in our experimental model (see Supplementary
material, Fig. S5). However, transferred SMARTA T cells
in the spleen expressed gut homing markers a4b7 follow-
ing priming with gp61 neo-antigen, which suggested that
increased homing of antigen-specific T cells to the intes-
tine could be one of the mechanisms that are responsible
for negatively regulating the gut epithelial integrity and
thereby promoting systemic bacterial translocation. How
exactly these T cells mediate this effect locally needs to be
further investigated. For example, other pro-inflammatory
cytokines including tumour necrosis factor-a, IL-6 or
interferon-c have been shown to promote apoptosis of
epithelial cells or modulate the expression of claudins,
which are tight junction proteins required for the regula-
tion of intestinal permeability.44–47 Importantly, increased
intestinal permeability has been involved in the
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pathogenesis of IBD48 and clinical studies have shown
that there is a decrease in the expression of tight junction
proteins in IBD patients.49 Although it is also possible
that activation of systemic anti-microbial CD4+ T cells
could impact on the function of innate lymphoid cells
that have been shown to be involved in anatomical con-
tainment of commensal bacteria,50 we found no differ-
ences in the innate compartment, in line with the notion
that the observed increased systemic bacterial transloca-
tion following DSS-induced gut epithelial damage is anti-
gen-specific T-cell driven. This demonstrates that
systemic antimicrobial T cells may have pathogenic con-
sequences under certain conditions.
Taken together, we demonstrate here that systemic
antimicrobial T-cell (hyper-)reactivity can have a detri-
mental effect on host–microbe mutualism. Elucidating the
mechanisms by which systemic antimicrobial T cells pro-
mote systemic bacterial translocation could therefore pro-
vide insights into the possible role of systemic
antimicrobial CD4+ T cells in the pathogenesis of IBD.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Schematic of the Escherichia coli ompC_gp61
signal peptide. A schematic of the ompC_gp61 construct is
shown.
Figure S2. In vivo antigen-specificity control using
ovalbumin (OVA) -specific CD4+ OT-II T cells. 3 9 107
CFSE-labelled CD4+ OT-II T cells were adoptively trans-
ferred into C57BL/6 recipients. The next day 108 CFU of
Escherichia coli ompC_gp61 or wild-type E. coli were
injected intravenously. As a positive control 50 lg of
OVA in combination with 5 nmol CpG were injected
intravenously. 5 days later OT-II T cell proliferation was
measured by flow cytometry. Data shown are representa-
tive of two independent experiments.
Figure S3. Intestinal permeability. Altered Schaedler
flora (ASF) colonized C57BL/6 mice were given 2% dex-
tran sodium sulphate in the drinking water or left
untreated. On day 2, 3 9 107 CFSE-labelled SMARTA T
cells were adoptively transferred and the next day mice
were gavaged with 1010 CFU wild-type Escherichia coli or
E. coli ompC_gp61. Albumin levels in the caecal content
were measured 6 days after bacterial challenge in the dif-
ferent experimental groups. Values shown are
mean  SD from three to four mice/group.
Figure S4. T-cell activation markers. Altered Schaedler
flora (ASF) colonized C57BL/6 mice were given 2% dex-
tran sodium sulphate in the drinking water or left
untreated. On day 2, 3 9 107 CFSE-labelled SMARTA T
cells were adoptively transferred and the next day mice
were gavaged with 1010 CFU wild-type Escherichia coli or
E. coli ompC_gp61. The indicated activation markers
were analysed by flow cytometry 6 days after bacterial
challenge in colon, mesenteric lymph nodes (MLN) and
spleen. Data represents mean  SD from three to four
mice/group. *P < 005, **P < 0005.
Figure S5. Absence of regulatory T (Treg) cell conver-
sion. (a) Altered Schaedler flora (ASF) colonized C57BL/6
mice were given 2% dextran sodium sulphate (DSS) in
the drinking water or left untreated. On day 2, 3 9 107
CFSE-labelled SMARTA T cells were adoptively trans-
ferred and the next day mice were gavaged with
1010 CFU wild-type Escherichia coli or E. coli ompC_gp61.
Treg cell conversion in colon, mesenteric lymph nodes
(MLN) and spleen was analysed by flow cytometry 6 days
after bacterial challenge. Representative dot plots from
three to four mice/group are shown. (b) ASF RAG-1/
mice were gavaged with 1010 CFU wild-type E. coli or
E. coli ompC_gp61. On day 1, mice were given 2% DSS
in the drinking water and also received 1 9 106 SMARTA
T cells intravenously on the same day. Homing to the
colon was analysed 12 days after bacterial challenge by
flow cytometry.
Figure S6. No changes in the intestinal innate immune
system and inflammatory status. Altered Schaedler flora
(ASF) colonized C57BL/6 mice were given 2% dextran
sodium sulphate (DSS) in the drinking water. On day 2,
3 9 107 CFSE-labelled SMARTA T cells were adoptively
transferred and the next day mice were gavaged with
1010 CFU wild-type Escherichia coli or E. coli ompC_gp61.
(a–e) All groups were analysed by flow cytometry 6 days
after bacterial challenge. (a) Representative dot plots
showing lineage negative (CD19 CD3) cells and (b)
MHC class II I-Ab positive cells in the small intestine
lamina propria. Proportions of (c) CD11b+ CD11c, (d)
CD11b+ CD11c+ and (e) CD11b CD11c+ in the small
intestine lamina propria are shown. Data represent pooled
data from two independent experiments with three or
four mice/group. (f) Serum levels of the indicated cytoki-
nes were measured. Data shown are from three pooled
independent experiments. The horizontal line represents
the geometric mean. The detection limit (DL) of the assay
is indicated by a dotted horizontal line.
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